Using specialized immune cells to treat a rare lung condition called LAM
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
This project is developing a new way to treat Lymphangioleiomyomatosis (LAM) by using specially trained immune cells to target and remove diseased cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11134429 on NIH RePORTER |
What this research studies
Lymphangioleiomyomatosis (LAM) is a rare lung condition that currently lacks a true cure. This project aims to create a new type of treatment using your body's own immune cells, called T cells. Researchers are designing these T cells to recognize specific markers found on LAM cells, similar to how they might fight off an infection. The goal is for these modified T cells to find and destroy LAM cells, while also being directed to the affected lung tissue to reduce side effects. This approach seeks to provide a more lasting solution than current therapies.
Who could benefit from this research
Good fit: Patients with Lymphangioleiomyomatosis (LAM) who are seeking new and potentially curative treatment options would be ideal candidates for future clinical applications of this research.
Not a fit: Patients without a diagnosis of Lymphangioleiomyomatosis (LAM) would not directly benefit from this specific therapy.
Why it matters
Potential benefit: If successful, this T-cell therapy could offer a true cure for women with LAM, going beyond the temporary relief provided by current treatments.
How similar studies have performed: Adoptive T-cell therapies, including CAR T cells, have shown success in treating certain cancers, suggesting a promising foundation for this novel approach in LAM.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Le Poole, I. Caroline — Northwestern University
- Study coordinator: Le Poole, I. Caroline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.